Astron (research center)

Astron
TypePrivate
IndustryBiotechnology, Precision oncology
Foundedc. 2024
HeadquartersUnited Kingdom / United States
Key people
  • Ben Whately (CEO)
  • Dr. Padman Vamadevan (CMO)
  • Myuran Balendran (CTO)
  • Travis Christoffersen (Co-founder)
Products
  • Polaris Research Report
  • Bioinformatics platform
Websiteastron.health

Astron is a precision oncology research company that develops bioinformatics platforms to support personalized cancer treatment. The company integrates genomic, transcriptomic, and proteomic data to improve treatment matching for cancer patients.[1][2]

Astron applies artificial intelligence (AI) to analyze existing drug libraries and identify potential drug repurposing opportunities in oncology.[3]

Operations

Astron was founded in 2024 to guide targeted cancer therapies.[4][5][6]

Astron's scientific advisory board includes academic oncologists and clinicians such as Dr. Shivan Sivakumar, associate professor of oncology at the University of Birmingham,[7][8] and Dr. D. Barry Boyd, assistant professor of medicine (medical oncology) at Yale School of Medicine and author of The Cancer Recovery Plan.[9][10] Ben Whately, co-founder of the language-learning platform Memrise, subsequently joined as CEO.[11]

Astron's methodology is informed by published research highlighting limitations of genomic-only testing, including a 2020 study showing that some tumors harbor potentially deleterious DNA mutations that are not expressed at the RNA level,[12] research demonstrating variable MAPK pathway activation in BRAF V600E–mutated melanoma despite identical genomic alterations and associated treatment resistance,[13] and a 2022 study indicating that pathway-based molecular signatures may predict treatment response more accurately than mutation status alone.[14]

Technology

Astron's platform integrates genomic, transcriptomic, and proteomic data to support treatment decision-making in oncology.[15]

The company also applies artificial intelligence to analyze published biomedical research in order to evaluate drug–target relationships and signaling pathways.[16]

Astron provides personalized research reports to patients through their referring oncologists, and its work has been referenced in published case studies describing integrative oncology approaches.[17][18]

References

  1. ↑ "AI is battling cancer, but not how you think". HealthcareToday.com. 15 September 2025. Retrieved 2026-04-28.
  2. ↑ "AI is battling cancer, but not how you think". The Journal of mHealth. 10 September 2025. Retrieved 2026-04-28.
  3. ↑ "AI is battling cancer, but not how you think". HTWorld Insight & Opinion. 11 August 2025. Retrieved 2026-04-28.
  4. ↑ "ASTRON HEALTH LTD overview - Find and update company information - GOV.UK". find-and-update.company-information.service.gov.uk. Retrieved 2026-04-28.
  5. ↑ "ASTRON HEALTH LTD overview – Find and update company information". Companies House, GOV.UK. Retrieved 2026-04-28.
  6. ↑ "AI is Battling Cancer, but not how you Think". The Journal of mHealth. September 10, 2025. Retrieved 2025-04-28.
  7. ↑ "Dr Shivan Sivakumar PhD FRCP". University of Birmingham Staff Profiles. Retrieved 2026-04-28.
  8. ↑ "AI is Battling Cancer, but not how you Think". The Journal of mHealth. September 10, 2025. Retrieved 2026-04-28.
  9. ↑ "D. Barry Boyd, MD – Hematology/Medical Oncology". Greenwich Hospital (Smilow Cancer Hospital/Yale Medicine). Retrieved 2026-04-28.
  10. ↑ "D. Barry Boyd, MD, MS". Yale School of Medicine – Yale Medicine. Retrieved 2026-04-28.
  11. ↑ "Memrise raises $15.5M as its AI-based language-learning app passes 35M users". TechCrunch. 2018-06-11. Retrieved 2026-04-21.
  12. ↑ Adashek, Jacob J.; Kato, Shumei; Parulkar, Rahul; Szeto, Christopher W.; Sanborn, J. Zachary; Vaske, Charles J.; Benz, Stephen C.; Reddy, Sandeep K.; Kurzrock, Razelle (2020-06-04). "Transcriptomic silencing as a potential mechanism of treatment resistance". JCI Insight. 5 (11): e134824, 134824. doi:10.1172/jci.insight.134824. ISSN 2379-3708. PMC 7308055. PMID 32493840.
  13. ↑ Darabi, Sourat; Stafford, Phillip; Braxton, David R.; Zuazo, Carlos E.; Brodie, Taylor J.; Demeure, Michael J. (2025-02-10). "BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome". International Journal of Molecular Sciences. 26 (16): 7910. doi:10.3390/ijms26167910. PMC 12386775. PMID 40869231.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Yao, Kevin; Zhou, Emily; Cheng, Chao (2022-02-01). "A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies". Cancer Medicine. 11 (4): 1232–1243. doi:10.1002/cam4.4491. ISSN 2045-7634. PMC 8855909. PMID 35044091.
  15. ↑ Jiang, Ziming; Zhang, Haoxuan; Gao, Yibo; Sun, Yingli (2025-11-21). "Multi-omics strategies for biomarker discovery and application in personalized oncology". Molecular Biomedicine. 6 (1): 115. doi:10.1186/s43556-025-00340-0. ISSN 2662-8651. PMC 12638490. PMID 41269529.
  16. ↑ Shivan Sivakumar (2025-09-15). "AI is battling cancer, but not how you think". Healthcare Today. Retrieved 2026-04-28.
  17. ↑ "From Stage 4 Cancer to Remission: The Power of Integrative Oncology". IMAhealth Substack. 2025-09-25. Retrieved 2026-04-28.
  18. ↑ Rocque, Gabrielle B.; Blum, Joanne L.; Ji, Yan; Pluard, Timothy; Migas, John; Lakhanpal, Shailendra; Jepsen, Erin; Gauthier, Eric; Wang, Yao; Montelongo, Monica Z.; Cappelleri, Joseph C.; Chen, Connie; Karuturi, Meghan S.; Tripathy, Debu (2025-10-01). "Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study". The Oncologist. 30 (10) oyaf281. doi:10.1093/oncolo/oyaf281. ISSN 1549-490X. PMC 12596709. PMID 40971858.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.